Roche wants FDA to expedite review of breast cancer drug

04/16/2010 | Bloomberg

Roche Holding said it will submit its breast cancer treatment T-DM1 to the FDA this year, aiming for approval later this year or early 2011. The compound, which was co-developed by Immunogen, combines a chemotherapy drug and breast cancer medicine Herceptin, which guides T-DM1 directly to cancer cells.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX